History and Mission
Inmedix was founded in 2006 by Andrew J Holman, MD, and Mr. Timothy Sciarrillo as a patent holding company for Dr. Holman’s discoveries. Its first project addressed the treatment of fibromyalgia with dopamine agonists, medications FDA-approved for the treatment of Parkinson’s disease. After three Inmedix studies, including a prospective, double-blind, randomized controlled trial, an Inmedix international utility patent portfolio was sold to a major pharmaceutical company.
During the first project, connections between stress, fibromyalgia and immune function were identified by Inmedix and other international researchers. Inmedix sought to examine how and why stress, controlled by the autonomic nervous system (ANS), might influence the severity of an autoimmune disease and its response to traditional treatment. Collaborating with the world leader in ANS testing in elite athletes, Omegawave Ltd (Espoo, Finland), Inmedix began to tease apart how stress in the brain impacts rheumatoid arthritis (RA) and other autoimmune diseases.